成都普瑞法科技开发有限公司欢迎您!
ISO ISO
CNAS CNAS
高新技术企业 高新技术企业
USP USP
知识产权管理体系认证证书 知识产权管理体系认证证书

文献列表

专业生产定制高含量植提产品和中药成分

您当前的位置:
期刊名:European Journal of Pharmacology
文献编号:
文献地址: https://www.sciencedirect.com/science/article/abs/pii/S0014299922000863
发表日期:10 March 2022
Pulmonary fibrosis (PF) is a chronic interstitial lung disease with unkown etiology. In the present study, we evaluated the anti-fibrotic effects of heterophyllin B, a natural product from radix pseudostellariae having anti-inflammatory and tyrosinase inhibitory activities. In bleomycin (BLM)-induced PF mouse model, heterophyllin B treatments (5 or 20 mg/kg/d) significantly attenuated BLM-induced alveolar cavity collapse, inflammatory cell infiltration, alveolar wall thickening and collagen deposition. When compared to model group, heterophyllin B treatments also increased adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) phosphorylation levels by 359% (P < 0.001) and reduced the expression of stimulator of interferon genes (STING) by 73% (P < 0.001). Furthermore, co-administration of heterophyllin B with AMPK inhibitor dorsomorphin (Compound C) significantly blocked the improvement effects of heterophyllin B on BLM-damaged lung tissue, and also increased the protein expression of STING which was inhibited by heterophyllin B in fibrotic lungs (P < 0.001). It is known that alveolar epithelia and lung fibroblasts exert prominent roles in the fibrosis progression. In the present study we found that, in vitro, heterophyllin B significantly inhibited alveolar epithelial mesenchymal transition (EMT) and lung fibroblast transdifferentiation. We also found that the inhibition of heterophyllin B on lung fibroblast transdifferentiation and STING expression was reversed by Compound C. To summarize, heterophyllin B exhibited protective effects on BLM-induced lung fibrosis potentially by inhibiting TGF-Smad2/3 signalings and AMPK-mediated STING signalings.
相关产品